Sangamo Therapeutics (NASDAQ: [[ticker:SGMO]]) has appointed Bettina Cockroft to serve as senior vice president and chief medical officer. Cockroft comes to Brisbane, CA-based Sangamo from Cytokinetics (NASDAQ: [[ticker:CYTK]]), where she was vice president of clinical research, neurology. Her experience also includes positions at Merck Serono, Novartis Consumer Health, and Menarini Ricerche. In July, Sangamo and partner Pfizer (NYSE: [[ticker:PFE]]) released data from an early stage study testing a gene therapy for hemophilia.